Although consideration of long-term outcomes and real-world data is needed, the role of upfront transplantation in patients with newly diagnosed MCL is likely limited to settings in which BTK inhibitors cannot be used in combination with immunochemotherapy or for maintenance. The gene discussed is BTK; the disease is mantle cell lymphoma.